Background: Volunteers in phase I/II HIV vaccine trials are assumed to be at low risk of acquiring HIV infection and are expected to have normal lives in the community. However, during participation in the trials, volunteers may encounter social harm and changes in their sexual behaviours. The current study aimed to study persistence of social harm and changes in sexual practices over time among phase I/II HIV vaccine immunogenicity (HIVIS03) trial volunteers in Dar es Salaam, Tanzania. Methods and Results: A descriptive prospective cohort study was conducted among 33 out of 60 volunteers of HIVIS03 trial in Dar es Salaam, Tanzania, who had received three HIV-1 DNA injections boosted with two HIV-1 MVA doses. A structured interview was admi...
Background: A number of countries in sub-Saharan Africa are preparing for HIV vaccine efficacy trial...
Background: A number of countries in sub-Saharan Africa are preparing for HIV vaccine efficacy tria...
Background: A number of countries in sub-Saharan Africa are preparing for HIV vaccine efficacy trial...
BACKGROUND: Volunteers in phase I/II HIV vaccine trials are assumed to be at low risk of acquiring H...
Volunteers in phase I/II HIV vaccine trials are assumed to be at low risk of acquiring HIV infection...
Volunteers in phase I/II HIV vaccine trials are assumed to be at low risk of acquiring HIV infection...
Background: Volunteers in phase I/II HIV vaccine trials are assumed to be at low risk of acquiring H...
Background: Increased sexual risk behaviour in participants enrolled in HIV prevention trials has be...
Evaluating experiences of volunteers in an HIV vaccine trial will be useful for the conduct of futur...
Background: Evaluating experiences of volunteers in an HIV vaccine trial will be useful for the cond...
BACKGROUND:The development of an effective preventive HIV vaccine is the best-known option to halt i...
Recruitment, enrollment and retention of volunteers in an HIV vaccine trial is important in the effo...
Recruitment, enrollment and retention of volunteers in an HIV vaccine trial is important in the effo...
Background: Research to discover an effective and safe vaccine is crucial to decrease HIV burden. Ho...
Background: A number of countries in sub-Saharan Africa are preparing for HIV vaccine efficacy tria...
Background: A number of countries in sub-Saharan Africa are preparing for HIV vaccine efficacy trial...
Background: A number of countries in sub-Saharan Africa are preparing for HIV vaccine efficacy tria...
Background: A number of countries in sub-Saharan Africa are preparing for HIV vaccine efficacy trial...
BACKGROUND: Volunteers in phase I/II HIV vaccine trials are assumed to be at low risk of acquiring H...
Volunteers in phase I/II HIV vaccine trials are assumed to be at low risk of acquiring HIV infection...
Volunteers in phase I/II HIV vaccine trials are assumed to be at low risk of acquiring HIV infection...
Background: Volunteers in phase I/II HIV vaccine trials are assumed to be at low risk of acquiring H...
Background: Increased sexual risk behaviour in participants enrolled in HIV prevention trials has be...
Evaluating experiences of volunteers in an HIV vaccine trial will be useful for the conduct of futur...
Background: Evaluating experiences of volunteers in an HIV vaccine trial will be useful for the cond...
BACKGROUND:The development of an effective preventive HIV vaccine is the best-known option to halt i...
Recruitment, enrollment and retention of volunteers in an HIV vaccine trial is important in the effo...
Recruitment, enrollment and retention of volunteers in an HIV vaccine trial is important in the effo...
Background: Research to discover an effective and safe vaccine is crucial to decrease HIV burden. Ho...
Background: A number of countries in sub-Saharan Africa are preparing for HIV vaccine efficacy tria...
Background: A number of countries in sub-Saharan Africa are preparing for HIV vaccine efficacy trial...
Background: A number of countries in sub-Saharan Africa are preparing for HIV vaccine efficacy tria...
Background: A number of countries in sub-Saharan Africa are preparing for HIV vaccine efficacy trial...